Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?

Biochemical Journal

Volumn 446, Issue 2, 2012, Pages 165-177

  Teich, Andrew F ^a   Arancio, Ottavio ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

amyloid; Alzheimer's disease; Hippocampus; Neuropathology; Synaptic

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; BETA SECRETASE; CALPAIN 1; CALPAIN 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GUANYLATE CYCLASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; KT 5823; NEU DIFFERENTIATION FACTOR; NITRIC OXIDE; PLACEBO; SEMAGACESTAT; SILDENAFIL; SMALL INTERFERING RNA; SOLANEZUMAB; UBIQUITIN C TERMINAL ESTERASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN;

ALZHEIMER DISEASE; BLEEDING; BRAIN EDEMA; DRUG WITHDRAWAL; EPIGENETICS; HUMAN; HYPOTHESIS; INTRACELLULAR SIGNALING; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; ELECTRICAL SYNAPSES; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; NOOTROPIC AGENTS; SIGNAL TRANSDUCTION;

EID: 84865191058     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20120653     Document Type: Review

References (203)

1. Maurer, K., Volk, S. and Gerbaldo, H. (1997) Auguste D and Alzheimer's disease. Lancet 349, 1546-1549 (Pubitemid 27216376)
2. Alzheimer, A. (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych. Gerichtl. Med. 64, 146-148
3. Alzheimer, A. (1911) Über eigenartige Krankheitsfälle des späteren Alters. Z. Gesamte Neurol. Psychiatr. 4, 356-385
4. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (Pubitemid 14104991)
5. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L. and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249 (Pubitemid 15053619)
6. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D. and Jones, E. (2011) Alzheimer's disease. Lancet 377, 1019-1031
7. Simmons, B. B., Hartmann, B. and Dejoseph, D. (2011) Evaluation of suspected dementia. Am. Fam. Physician 84, 895-902
8. Chow, V. W., Mattson, M. P., Wong, P. C. and Gleichmann, M. (2010) An overview of APP processing enzymes and products. NeuroMol. Med. 12, 1-12
9. Bekris, L. M., Yu, C. E., Bird, T. D. and Tsuang, D. W. (2010) Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23, 213-227
10. Tanzi, R. E., Kovacs, D. M., Kim, T. W., Moir, R. D., Guenette, S. Y. and Wasco, W. (1996) The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3, 159-168 (Pubitemid 26391319)
11. Bertram, L., Lill, C. M. and Tanzi, R. E. (2010) The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281
12. Goate, A. and Hardy, J. (2012) Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. 120, 3-8
13. Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
14. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131-1135 (Pubitemid 14027629)
15. Yankner, B. A., Duffy, L. K. and Kirschner, D. A. (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250, 279-282
16. Frautschy, S. A., Baird, A. and Cole, G. M. (1991) Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. Natl. Acad. Sci. U.S.A. 88, 8362-8366 (Pubitemid 21915356)
17. Pike, C. J., Walencewicz, A. J., Glabe, C. G. and Cotman, C. W. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314
18. Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E. and Klug, A. (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U.S.A. 85, 4051-4055
19. Mudher, A. and Lovestone, S. (2002) Alzheimer's disease: do tauists and baptists finally shake hands? Trends Neurosci. 25, 22-26 (Pubitemid 34093781)
20. Nagy, Z., Esiri, M. M., Jobst, K. A., Morris, J. H., King, E. M., McDonald, B., Litchfield, S., Smith, A., Barnetson, L. and Smith, A. D. (1995) Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6, 21-31
21. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A. et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705
22. Karran, E., Mercken, M. and De Strooper, B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discovery 10, 698-712
23. Ghosh, A. K., Brindisi, M. and Tang, J. (2012) Developing β-secretase inhibitors for treatment of Alzheimer's disease. J. Neurochem. 120, 71-83
24. Herrmann, N., Chau, S. A., Kircanski, I. and Lanctot, K. L. (2011) Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 71, 2031-2065
25. Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., Demattos, R. B., May, P. C. et al. (2009) A γ -secretase inhibitor decreases amyloid-β production in the central nervous system. Ann. Neurol. 66, 48-54
26. Eli Lilly (2010) Lilly halts development of Semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials, http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794
27. Haass, C. and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (Pubitemid 46432529)
28. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A. et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
29. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A. and Klein, W. L. (2003) Alzheimer's disease-affected brain: presence of oligomeric A βligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 100, 10417-10422 (Pubitemid 37071893)
30. Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J. et al. (2007) Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28, 537-547 (Pubitemid 46282205)
31. Saumier, D., Duong, A., Haine, D., Garceau, D. and Sampalis, J. (2009) Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. J Nutr. Health Aging 13, 808-812
32. Fenili, D., Brown, M., Rappaport, R. and McLaurin, J. (2007) Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J. Mol. Med. 85, 603-611 (Pubitemid 46870891)
33. McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F. et al. (2006) Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808 (Pubitemid 44050070)
34. Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C. et al. (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77, 1253-1262
35. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R. et al. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779-786
36. Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F. et al. (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562 (Pubitemid 40617691)
37. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H. et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070
38. Siemers, E. R., Friedrich, S., Dean, R. A., Gonzales, C. R., Farlow, M. R., Paul, S. M. and Demattos, R. B. (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33, 67-73
39. Delrieu, J., Ousset, P. J., Caillaud, C. and Vellas, B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J. Neurochem. 120, 186-193
40. Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A. and Panza, F. (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev. Clin. Immunol. 8, 135-149
41. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, Jr, C. R., Kaye, J., Montine, T. J. et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 7, 280-292
42. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (Pubitemid 14076461)
43. Khachaturian, Z. S. (1985) Diagnosis of Alzheimer's disease. Arch. Neurol. 42, 1097-1105
44. Morris, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D. and Clark, C. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165 (Pubitemid 19239715)
45. Hyman, B. T. (1997) The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol. Aging 18, S27-S32
46. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, Jr, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R. et al. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 7, 263-269
47. Tierney, M. C., Fisher, R. H., Lewis, A. J., Zorzitto, M. L., Snow, W. G., Reid, D. W. and Nieuwstraten, P. (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 38, 359-364 (Pubitemid 18083667)
48. Flicker, C., Ferris, S. H. and Reisberg, B. (1993) A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 6, 84-96 (Pubitemid 23183395)
49. Reisberg, B., Ferris, S. H., de Leon, M. J. and Crook, T. (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139, 1136-1139 (Pubitemid 12051593)
50. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G. and Kokmen, E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308 (Pubitemid 29120227)
51. Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H. et al. (2006) Mild cognitive impairment. Lancet 367, 1262-1270
52. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C. et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 7, 270-279
53. Blennow, K. (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225
54. Wang, J., Dickson, D. W., Trojanowski, J. Q. and Lee, V. M. (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328-337 (Pubitemid 29382824)
55. Blennow, K., Vanmechelen, E. and Hampel, H. (2001) CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24, 87-97 (Pubitemid 34066679)
56. Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A. and Poser, S. (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225, 210-212 (Pubitemid 27191632)
57. Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P. and Blennow, K. (2000) Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimer's Dis. 2, 199-206 (Pubitemid 32095607)
58. Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Forstl, H. and Kurz, A. (2003) Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry 8, 343-347 (Pubitemid 36712928)
59. De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P. P., Coart, E., Hansson, O., Minthon, L., Zetterberg, H. et al. (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949-956
60. Stomrud, E., Hansson, O., Blennow, K., Minthon, L. and Londos, E. (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dementia Geriatr. Cognit. Disord. 24, 118-124 (Pubitemid 47094071)
61. Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H. and Blennow, K. (2007) Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 78, 461-464
62. Skoog, I., Davidsson, P., Aevarsson, O., Vanderstichele, H., Vanmechelen, E. and Blennow, K. (2003) Cerebrospinal fluid β-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dementia Geriatr. Cognit. Disord. 15, 169-176 (Pubitemid 36206647)
63. Mathis, C. A., Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., Holt, D. P., Wang, Y., Huang, G. F., Debnath, M. L. et al. (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12, 295-298 (Pubitemid 34113887)
64. Villemagne, V. L. and Rowe, C. C. (2011) Amyloid imaging. Int. Psychogeriatr. 23, S41-S49
65. Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L. and Rowe, C. C. (2007) β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844 (Pubitemid 350033975)
66. Villemagne, V. L., Fodero-Tavoletti, M. T., Pike, K. E., Cappai, R., Masters, C. L. and Rowe, C. C. (2008) The ART of loss: Aβ imaging in the evaluation of Alzheimer's disease and other dementias. Mol. Neurobiol. 38, 1-15
67. Villemagne, V. L., Pike, K. E., Chetelat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O. et al. (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 69, 181-192
68. Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G. et al. (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275-1283
69. Stern, R. A., Riley, D. O., Daneshvar, D. H., Nowinski, C. J., Cantu, R. C. and McKee, A. C. (2011) Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. PM&R 3, S460-S467
70. Wolfe, M. S. (2012) γ -Secretase inhibitors and modulators for Alzheimer's disease. J. Neurochem. 120, 89-98
71. Haapasalo, A. and Kovacs, D. M. (2011) The many substrates of presenilin/γ-secretase. J. Alzheimer's Dis. 25, 3-28
72. Bossy-Wetzel, E., Schwarzenbacher, R. and Lipton, S. A. (2004) Molecular pathways to neurodegeneration. Nat. Med. 10, S2-S9 (Pubitemid 38901861)
73. Querfurth, H. W. and LaFerla, F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344
74. Struhl, G. and Adachi, A. (2000) Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol. Cell 6, 625-636
75. Artavanis-Tsakonas, S. and Muskavitch, M. A. (2010) Notch: the past, the present, and the future. Curr. Top. Dev. Biol. 92, 1-29
76. Kopan, R. and Ilagan, M. X. (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233
77. Klusza, S. and Deng, W. M. (2011) At the crossroads of differentiation and proliferation: precise control of cell-cycle changes by multiple signaling pathways in Drosophila follicle cells. BioEssays 33, 124-134
78. Udolph, G. (2012) Notch signaling and the generation of cell diversity in Drosophila neuroblast lineages. Adv. Exp. Med. Biol. 727, 47-60
79. Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D. and Srivastava, D. (2005) Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270-274 (Pubitemid 41294491)
80. Gridley, T. (2003) Notch signaling and inherited disease syndromes. Hum. Mol. Genet. 12, R9-R13
81. Louvi, A., Arboleda-Velasquez, J. F. and Artavanis-Tsakonas, S. (2006) CADASIL: a critical look at a Notch disease. Dev. Neurosci. 28, 5-12
82. Lobry, C., Oh, P. and Aifantis, I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 208, 1931-1935
83. He, G., Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P. et al. (2010) γ-Secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95-98
84. Chang, K. A. and Suh, Y. H. (2010) Possible roles of amyloid intracellular domain of amyloid precursor protein. BMB Rep. 43, 656-663
85. Pardossi-Piquard, R. and Checler, F. (2012) The physiology of the β-amyloid precursor protein intracellular domain AICD. J. Neurochem. 120, 109-124
86. Hamid, R., Kilger, E., Willem, M., Vassallo, N., Kostka, M., Bornhovd, C., Reichert, A. S., Kretzschmar, H. A., Haass, C. and Herms, J. (2007) Amyloid precursor protein intracellular domain modulates cellular calcium homeostasis and ATP content. J. Neurochem. 102, 1264-1275 (Pubitemid 47174237)
87. Ghosal, K., Vogt, D. L., Liang, M., Shen, Y., Lamb, B. T. and Pimplikar, S. W. (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. U.S.A. 106, 18367-18372
88. Nakayama, K., Ohkawara, T., Hiratochi, M., Koh, C. S. and Nagase, H. (2008) The intracellular domain of amyloid precursor protein induces neuron-specific apoptosis. Neurosci. Lett. 444, 127-131
89. Vazquez, M. C., Vargas, L. M., Inestrosa, N. C. and Alvarez, A. R. (2009) c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis. J. Cell. Physiol. 220, 136-143
90. Kinoshita, A., Whelan, C. M., Berezovska, O. and Hyman, B. T. (2002) The γsecretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J. Biol. Chem. 277, 28530-28536 (Pubitemid 41079279)
91. Passer, B., Pellegrini, L., Russo, C., Siegel, R. M., Lenardo, M. J., Schettini, G., Bachmann, M., Tabaton, M. and D'Adamio, L. (2000) Generation of an apoptotic intracellular peptide by γ-secretase cleavage of Alzheimer's amyloid β protein precursor. J. Alzheimer's Dis. 2, 289-301 (Pubitemid 32095613)
92. Ozaki, T., Li, Y., Kikuchi, H., Tomita, T., Iwatsubo, T. and Nakagawara, A. (2006) The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. Biochem. Biophys. Res. Commun. 351, 57-63 (Pubitemid 44635406)
93. Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St George-Hyslop, P. and Checler, F. (2006) Presenilin-dependent γ-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J. Neurosci. 26, 6377-6385
94. Wang, S., Wang, R., Chen, L., Bennett, D. A., Dickson, D. W. and Wang, D. S. (2010) Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J. Neurochem. 115, 47-57
95. Nalivaeva, N. N., Beckett, C., Belyaev, N. D. and Turner, A. J. (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J. Neurochem. 120, 167-185
96. Pardossi-Piquard, R., Petit, A., Kawarai, T., Sunyach, C., Alves da Costa, C., Vincent, B., Ring, S., D'Adamio, L., Shen, J., Muller, U. et al. (2005) Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP. Neuron 46, 541-554 (Pubitemid 40797380)
97. Pardossi-Piquard, R., Dunys, J., Yu, G., St George-Hyslop, P., Alves da Costa, C. and Checler, F. (2006) Neprilysin activity and expression are controlled by nicastrin. J. Neurochem. 97, 1052-1056
98. Hemming, M. L., Elias, J. E., Gygi, S. P. and Selkoe, D. J. (2009) Identification of β-secretase (BACE1) substrates using quantitative proteomics. PLoS ONE 4, e8477
99. Kandalepas, P. C. and Vassar, R. (2012) Identification and biology of β-secretase. J. Neurochem. 120, 55-61
100. Eggert, S., Paliga, K., Soba, P., Evin, G., Masters, C. L., Weidemann, A. and Beyreuther, K. (2004) The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves α-, β-, γ-, and ε-like cleavages: modulation of APLP-1 processing by n-glycosylation. J. Biol. Chem. 279, 18146-18156 (Pubitemid 38623227)
101. Li, Q. and Sudhof, T. C. (2004) Cleavage of amyloid-β precursor protein and amyloid-βprecursor-like protein by BACE 1. J. Biol. Chem. 279, 10542-10550 (Pubitemid 38372665)
102. Pastorino, L., Ikin, A. F., Lamprianou, S., Vacaresse, N., Revelli, J. P., Platt, K., Paganetti, P., Mathews, P. M., Harroch, S. and Buxbaum, J. D. (2004) BACE (β-secretase) modulates the processing of APLP2 in vivo. Mol. Cell. Neurosci. 25, 642-649 (Pubitemid 38481473)
103. von Arnim, C. A., Kinoshita, A., Peltan, I. D., Tangredi, M. M., Herl, L., Lee, B. M., Spoelgen, R., Hshieh, T. T., Ranganathan, S., Battey, F. D. et al. (2005) The low density lipoprotein receptor-related protein (LRP) is a novel β-secretase (BACE1) substrate. J. Biol. Chem. 280, 17777-17785 (Pubitemid 41389016)
104. Kim, D. Y., Ingano, L. A., Carey, B. W., Pettingell, W. H. and Kovacs, D. M. (2005) Presenilin/γ-secretase-mediated cleavage of the voltage-gated sodium channel β2-subunit regulates cell adhesion and migration. J. Biol. Chem. 280, 23251-23261 (Pubitemid 40853237)
105. Wong, H. K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P. and Nukina, N. (2005) β Subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-secretase. J. Biol. Chem. 280, 23009-23017 (Pubitemid 40853211)
106. Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D. and Yan, R. (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9, 1520-1525 (Pubitemid 44862660)
107. Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C. and Haass, C. (2006) Control of peripheral nerve myelination by the β-secretase BACE1. Science 314, 664-666 (Pubitemid 44646394)
108. Hu, X., He, W., Diaconu, C., Tang, X., Kidd, G. J., Macklin, W. B., Trapp, B. D. and Yan, R. (2008) Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J. 22, 2970-2980
109. May, P. C., Dean, R. A., Lowe, S. L., Martenyi, F., Sheehan, S. M., Boggs, L. N., Monk, S. A., Mathes, B. M., Mergott, D. J., Watson, B. M. et al. (2011) Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J. Neurosci. 31, 16507-16516
110. Chasseigneaux, S. and Allinquant, B. (2012) Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J. Neurochem. 120, 99-108
111. Chasseigneaux, S., Dinc, L., Rose, C., Chabret, C., Coulpier, F., Topilko, P., Mauger, G. and Allinquant, B. (2011) Secreted amyloid precursor protein β and secreted amyloid precursor protein α induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS ONE 6, e16301
112. Freude, K. K., Penjwini, M., Davis, J. L., LaFerla, F. M. and Blurton-Jones, M. (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J. Biol. Chem. 286, 24264-24274
113. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M. et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 8844-8853 (Pubitemid 37210896)
114. Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C. and Pearson, H. A. (2003) The production of amyloid β peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23, 5531-5535 (Pubitemid 36807828)
115. Lopez-Toledano, M. A. and Shelanski, M. L. (2004) Neurogenic effect of β-amyloid peptide in the development of neural stem cells. J. Neurosci. 24, 5439-5444 (Pubitemid 38747685)
116. Cirrito, J. R., Yamada, K. A., Finn,M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S. and Holtzman, D. M. (2005) Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48, 913-922 (Pubitemid 41814696)
117. Cirrito, J. R., Kang, J. E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., Bu, G., Mennerick, S. and Holtzman, D. M. (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron 58, 42-51 (Pubitemid 351467029)
118. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S. and Malinow, R. (2003) APP processing and synaptic function. Neuron 37, 925-937 (Pubitemid 36398299)
119. Abramov, E., Dolev, I., Fogel, H., Ciccotosto, G. D., Ruff, E. and Slutsky, I. (2009) Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567-1576
120. Puzzo, D., Privitera, L., Fa', M., Staniszewski, A., Hashimoto, G., Aziz, F., Sakurai, M., Ribe, E. M., Troy, C. M., Mercken, M. et al. (2011) Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 69, 819-830
121. Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri, A. and Arancio, O. (2008) Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537-14545
122. Brody, D. L., Magnoni, S., Schwetye, K. E., Spinner, M. L., Esparza, T. J., Stocchetti, N., Zipfel, G. J. and Holtzman, D. M. (2008) Amyloid-β dynamics correlate with neurological status in the injured human brain. Science 321, 1221-1224
123. Puzzo, D., Privitera, L. and Palmeri, A. (2012) Hormetic effect of amyloid-β peptide in synaptic plasticity and memory. Neurobiol. Aging 1484, e15-e24
124. Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E. et al. (2004) Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 24, 10191-10200 (Pubitemid 39492046)
125. Lacor, P. N., Buniel, M. C., Furlow, P. W., Clemente, A. S., Velasco, P. T., Wood, M., Viola, K. L. and Klein, W. L. (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796-807 (Pubitemid 46174498)
126. Mukaetova-Ladinska, E. B., Garcia-Siera, F., Hurt, J., Gertz, H. J., Xuereb, J. H., Hills, R., Brayne, C., Huppert, F. A., Paykel, E. S., McGee, M. et al. (2000) Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am. J. Pathol. 157, 623-636 (Pubitemid 30626921)
127. Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J. and Sabatini, B. L. (2007) Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (Pubitemid 46438992)
128. Scheff, S. W., Price, D. A., Schmitt, F. A., Scheff, M. A. and Mufson, E. J. (2011) Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J. Alzheimer's Dis. 24, 547-557
129. Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V., Hyman, B. T. et al. (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271-276 (Pubitemid 30491299)
130. Giacchino, J., Criado, J. R., Games, D. and Henriksen, S. (2000) In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice. Brain Res. 876, 185-190
131. Larson, J., Lynch, G., Games, D. and Seubert, P. (1999) Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 840, 23-35 (Pubitemid 29434821)
132. D'Hooge, R., Nagels, G., Westland, C. E., Mucke, L. and De Deyn, P. P. (1996) Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein. NeuroReport 7, 2807-2811 (Pubitemid 26403065)
133. Yamaguchi, F., Richards, S. J., Beyreuther, K., Salbaum, M., Carlson, G. A. and Dunnett, S. B. (1991) Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory. NeuroReport 2, 781-784
134. Bramham, C. R. (2008) Local protein synthesis, actin dynamics, and LTP consolidation. Curr. Opin. Neurobiol. 18, 524-531
135. Abel, T., Nguyen, P. V., Barad, M., Deuel, T. A., Kandel, E. R. and Bourtchouladze, R. (1997) Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 88, 615-626 (Pubitemid 27152404)
136. Bach, M. E., Barad, M., Son, H., Zhuo, M., Lu, Y. F., Shih, R., Mansuy, I., Hawkins, R. D. and Kandel, E. R. (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitroand are attenuated by drugs that enhance the cAMP signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 96, 5280-5285 (Pubitemid 29214574)
137. Silva, A. J., Kogan, J. H., Frankland, P. W. and Kida, S. (1998) CREB and memory. Annu. Rev. Neurosci. 21, 127-148 (Pubitemid 28150661)
138. Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O. and Shelanski, M. (2002) Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U.S.A. 99, 13217-13221
139. Arendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C. E. and Diamond, D. M. (2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891, 42-53 (Pubitemid 32115494)
140. Battaglia, F., Trinchese, F., Liu, S., Walter, S., Nixon, R. A. and Arancio, O. (2003) Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J. Mol. Neurosci. 20, 357-362 (Pubitemid 38146994)
141. Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P. M. and Arancio, O. (2004) Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol. 55, 801-814 (Pubitemid 38702575)
142. Viosca, J., Malleret, G., Bourtchouladze, R., Benito, E., Vronskava, S., Kandel, E. R. and Barco, A. (2009) Chronic enhancement of CREB activity in the hippocampus interferes with the retrieval of spatial information. Learn. Mem. 16, 198-209
143. Barco, A., Pittenger, C. and Kandel, E. R. (2003) CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin. Ther. Targets 7, 101-114 (Pubitemid 36204592)
144. Cho, E. C., Mitton, B. and Sakamoto, K. M. (2011) CREB and leukemogenesis. Crit. Rev. Oncog. 16, 37-46
145. Arancio, O., Kiebler, M., Lee, C. J., Lev-Ram, V., Tsien, R. Y., Kandel, E. R. and Hawkins, R. D. (1996) Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell 87, 1025-1035 (Pubitemid 26427986)
146. Bon, C. L. and Garthwaite, J. (2003) On the role of nitric oxide in hippocampal long-term potentiation. J. Neurosci. 23, 1941-1948 (Pubitemid 36314749)
147. Ohki, K., Yoshida, K., Hagiwara, M., Harada, T., Takamura, M., Ohashi, T., Matsuda, H. and Imaki, J. (1995) Nitric oxide induces c-fos gene expression via cyclic AMP response element binding protein (CREB) phosphorylation in rat retinal pigment epithelium. Brain Res. 696, 140-144
148. Gudi, T., Huvar, I., Meinecke, M., Lohmann, S. M., Boss, G. R. and Pilz, R. B. (1996) Regulation of gene expression by cGMP-dependent protein kinase. Transactivation of the c-fos promoter. J. Biol. Chem. 271, 4597-4600
149. Lu, Y. F., Kandel, E. R. and Hawkins, R. D. (1999) Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci. 19, 10250-10261 (Pubitemid 30228032)
150. Garthwaite, J. and Boulton, C. L. (1995) Nitric oxide signaling in the central nervous system. Annu. Rev. Physiol. 57, 683-706
151. Lohmann, S. M., Vaandrager, A. B., Smolenski, A., Walter, U. and De Jonge, H. R. (1997) Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem. Sci. 22, 307-312 (Pubitemid 27327088)
152. Puzzo, D., Vitolo, O., Trinchese, F., Jacob, J. P., Palmeri, A. and Arancio, O. (2005) Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 25, 6887-6897 (Pubitemid 41023156)
153. Monfort, P., Munoz, M. D., Kosenko, E. and Felipo, V. (2002) Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. J. Neurosci. 22, 10116-10122 (Pubitemid 35416850)
154. Puzzo, D., Staniszewski, A., Deng, S. X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D. W. et al. (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer's disease mouse model. J. Neurosci. 29, 8075-8086
155. Huang, Y. and Wang, K. K. (2001) The calpain family and human disease. Trends Mol. Med. 7, 355-362 (Pubitemid 32735021)
156. Nixon, R. A. (2003) The calpains in aging and aging-related diseases. Ageing Res. Rev. 2, 407-418
157. Perlmutter, L. S., Siman, R., Gall, C., Seubert, P., Baudry, M. and Lynch, G. (1988) The ultrastructural localization of calcium-activated protease 'calpain' in rat brain. Synapse 2, 79-88 (Pubitemid 18059397)
158. Saito, K., Elce, J. S., Hamos, J. E. and Nixon, R. A. (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 90, 2628-2632 (Pubitemid 23113469)
159. Grynspan, F., Griffin, W. R., Cataldo, A., Katayama, S. and Nixon, R. A. (1997) Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. 763, 145-158 (Pubitemid 27364434)
160. Wang, K. K. (2000) Calpain and caspase: can you tell the difference? Trends Neurosci. 23, 20-26
161. Siman, R., Card, J. P. and Davis, L. G. (1990) Proteolytic processing of β-amyloid precursor by calpain I. J. Neurosci. 10, 2400-2411
162. Chen, M., Durr, J. and Fernandez, H. L. (2000) Possible role of calpain in normal processing of β-amyloid precursor protein in human platelets. Biochem. Biophys. Res. Commun. 273, 170-175 (Pubitemid 30426881)
163. Mathews, P. M., Jiang, Y., Schmidt, S. D., Grbovic, O. M., Mercken, M. and Nixon, R. A. (2002) Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of clapains enhances endosomal generation of β-cleaved C-terminal APP fragments. J. Biol. Chem. 277, 36415-36424
164. Steiner, H., Capell, A., Pesold, B., Citron, M., Kloetzel, P. M., Selkoe, D. J., Romig, H., Mendla, K. and Haass, C. (1998) Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273, 32322-32331 (Pubitemid 29177180)
165. Zhang, L., Song, L. and Parker, E. M. (1999) Calpain inhibitor I increases β-amyloid peptide production by inhibiting the degradation of the substrate of γ-secretase. Evidence that substrate availability limits beta-amyloid peptide production. J. Biol. Chem. 274, 8966-8972 (Pubitemid 29164699)
166. Pontremoli, S., Melloni, E., Michetti, M., Sparatore, B., Salamino, F., Sacco, O. and Horecker, B. L. (1987) Phosphorylation and proteolytic modification of specific cytoskeletal proteins in human neutrophils stimulated by phorbol 12-myristate 13-acetate. Proc. Natl. Acad. Sci. U.S.A. 84, 3604-3608 (Pubitemid 17088329)
167. 2+/calmodulin-dependent protein kinase II. Proc. Natl. Acad. Sci. U.S.A. 85, 6218-6221
168. Wang, K. K. and Yuen, P. W. (1997) Development and therapeutic potential of calpain inhibitors. Adv. Pharmacol. 37, 117-152
169. Banno, Y., Nakashima, S., Hachiya, T. and Nozawa, Y. (1995) Endogenous cleavage of phospholipase C-β3 by agonist-induced activation of calpain in human platelets. J. Biol. Chem. 270, 4318-4324
170. Lee, M. S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M. and Tsai, L. H. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364 (Pubitemid 30337070)
171. Carillo, S., Pariat, M., Steff, A. M., Roux, P., Etienne-Julan, M., Lorca, T. and Piechaczyk, M. (1994) Differential sensitivity of FOS and JUN family members to calpains. Oncogene 9, 1679-1689 (Pubitemid 24163395)
172. Lin, Y. C., Brown, K. and Siebenlist, U. (1995) Activation of NF-κB requires proteolysis of the inhibitor IκB-α: signal-induced phosphorylation of IκB-α alone does not release active NF-κB. Proc. Natl. Acad. Sci. U.S.A. 92, 552-556
173. Mbebi, C., See, V., Mercken, L., Pradier, L., Muller, U. and Loeffler, J. P. (2002) Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway. J. Biol. Chem. 277, 20979-20990 (Pubitemid 34967409)
174. Siman, R., Baudry, M. and Lynch, G. (1984) Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. Proc. Natl. Acad. Sci. U.S.A. 81, 3572-3576 (Pubitemid 14122716)
175. Johnson, G. V., Litersky, J. M. and Jope, R. S. (1991) Degradation of microtubule-associated protein 2 and brain spectrin by calpain: a comparative study. J. Neurochem. 56, 1630-1638
176. Yuen, E. Y., Liu, W. and Yan, Z. (2007) The phosphorylation state of GluR1 subunits determines the susceptibility of AMPA receptors to calpain cleavage. J. Biol. Chem. 282, 16434-16440 (Pubitemid 47100393)
177. Wu, Y., Liang, S., Oda, Y., Ohmori, I., Nishiki, T., Takei, K., Matsui, H. and Tomizawa, K. (2007) Truncations of amphiphysin I by calpain inhibit vesicle endocytosis during neural hyperexcitation. EMBO J. 26, 2981-2990 (Pubitemid 46975790)
178. Shimizu, K., Phan, T., Mansuy, I. M. and Storm, D. R. (2007) Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. Cell 128, 1219-1229 (Pubitemid 46427874)
179. Trinchese, F., Fa, M., Liu, S., Zhang, H., Hidalgo, A., Schmidt, S. D., Yamaguchi, H., Yoshii, N., Mathews, P. M., Nixon, R. A. et al. (2008) Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin. Invest. 118, 2796-2807
180. de Vrij, F. M., Fischer, D. F., van Leeuwen, F. W. and Hol, E. M. (2004) Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog. Neurobiol. 74, 249-270 (Pubitemid 39586719)
181. Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L. S. and Li, L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 13256-13264 (Pubitemid 38445905)
182. Chain, D. G., Casadio, A., Schacher, S., Hegde, A. N., Valbrun, M., Yamamoto, N., Goldberg, A. L., Bartsch, D., Kandel, E. R. and Schwartz, J. H. (1999) Mechanisms for generating the autonomous cAMP-dependent protein kinase required for long-term facilitation in Aplysia. Neuron 22, 147-156 (Pubitemid 29070101)
183. Ichihara, N., Wu, J., Chui, D. H., Yamazaki, K., Wakabayashi, T. and Kikuchi, T. (1995) Axonal degeneration promotes abnormal accumulation of amyloid β-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Brain Res. 695, 173-178
184. Saigoh, K., Wang, Y. L., Suh, J. G., Yamanishi, T., Sakai, Y., Kiyosawa, H., Harada, T., Ichihara, N., Wakana, S., Kikuchi, T. et al. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23, 47-51 (Pubitemid 29418786)
185. Gong, B., Cao, Z., Zheng, P., Vitolo, O. V., Liu, S., Staniszewski, A., Moolman, D., Zhang, H., Shelanski, M. and Arancio, O. (2006) Ubiquitin hydrolase Uch-L1 rescues β-amyloid-induced decreases in synaptic function and contextual memory. Cell 126, 775-788 (Pubitemid 44233627)
186. Liu, Z., Meray, R. K., Grammatopoulos, T. N., Fredenburg, R. A., Cookson, M. R., Liu, Y., Logan, T. and Lansbury, Jr, P. T. (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 106, 4635-4640
187. Smith, D. L., Pozueta, J., Gong, B., Arancio, O. and Shelanski, M. (2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U.S.A. 106, 16877-16882
188. Gong, B. and Leznik, E. (2007) The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect. 20, 365-370 (Pubitemid 350219068)
189. Gong, B., Chen, F., Pan, Y., Arrieta-Cruz, I., Yoshida, Y., Haroutunian, V. and Pasinetti, G. M. (2010) SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell 9, 1018-1031
190. Vecsey, C. G., Hawk, J. D., Lattal, K. M., Stein, J. M., Fabian, S. A., Attner, M. A., Cabrera, S. M., McDonough, C. B., Brindle, P. K., Abel, T. et al. (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J. Neurosci. 27, 6128-6140 (Pubitemid 46890024)
191. +/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947-959
192. Korzus, E., Rosenfeld, M. G. and Mayford, M. (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961-972 (Pubitemid 38798234)
193. Levenson, J. M., O'Riordan, K. J., Brown, K. D., Trinh, M. A., Molfese, D. L. and Sweatt, J. D. (2004) Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545-40559 (Pubitemid 39287646)
194. Abel, T. and Zukin, R. S. (2008) Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8, 57-64
195. Saura, C. A., Choi, S. Y., Beglopoulos, V., Malkani, S., Zhang, D., Shankaranarayana Rao, B. S., Chattarji, S., Kelleher, III, R. J., Kandel, E. R., Duff, K. et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42, 23-36 (Pubitemid 38456965)
196. Francis, Y. I., Stephanou, A. and Latchman, D. S. (2006) CREB-binding protein activation by presenilin 1 but not by its M146L mutant. NeuroReport 17, 917-921 (Pubitemid 43869959)
197. Caccamo, A., Maldonado, M. A., Bokov, A. F., Majumder, S. and Oddo, S. (2010) CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 107, 22687-22692
198. Roelfsema, J. H. and Peters, D. J. (2007) Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev. Mol. Med. 9, 1-16 (Pubitemid 47616466)
199. Maurice, T., Duclot, F., Meunier, J., Naert, G., Givalois, L., Meffre, J., Celerier, A., Jacquet, C., Copois, V., Mechti, N. et al. (2008) Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neuropsychopharmacology 33, 1584-1602 (Pubitemid 351684713)
200. Francis, I. Y., Fa', M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D. and Arancio, O. (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimer's Dis. 18, 131-139
201. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M. and Tsai, L. H. (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178-182 (Pubitemid 46763080)
202. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M. et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179 (Pubitemid 47057498)
203. Graff, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M., Nieland, T. J., Fass, D. M., Kao, P. F., Kahn, M. et al. (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222-226